BCL6 and B-cell non-Hodgkin lymphoma: Importantly, all of these inhibitors act by blocking the interaction between BCL6 and its co-repressors, resulting in re-expression of BCL6 target genes, proliferation arrest and apoptosis in B-cell lymphoma xenografts.